Update on KOMET-001: identifying the optimal dose of ziftomenib for patients with R/R AML скачать в хорошем качестве

Update on KOMET-001: identifying the optimal dose of ziftomenib for patients with R/R AML

Harry Erba, MD, PhD, Duke University, Durham, NC, outlines preliminary data from an ongoing Phase I/II study of ziftomenib in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) (NCT04067336). So far, the Phase Ia results demonstrate a manageable safety profile and preliminary efficacy of ziftomenib in patients with AML. The phase Ib study determined the optimal biologically active dose for the inhibitor and suggested that with appropriate differentiation syndrome management, ziftomenib is well tolerated. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.